Literature DB >> 9712728

Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene.

O Bakker1, F Hudig, S Meijssen, W M Wiersinga.   

Abstract

Treatment of patients with amiodarone, a potent anti arrhythmic drug, increases plasma LDL cholesterol levels, similar to that seen during hypothyroidism. This increase is the result of a decreased expression of the hepatic LDL receptor gene. We investigated the effects of thyroid hormone, amiodarone and desethylamiodarone on the first 687 bp upstream of the first ATG of the human LDL receptor gene by co-transfection with TRbeta1 into HepG2 cells. Promoter activity showed a dose-dependent increase upon addition of thyroid hormone up to a maximum of 600% at 10(-6) M T3. Using 5'-deletions it was found that a functional TRE(s) is present between -687 bp and -160 bp upstream of the ATG of the LDL receptor gene. Amiodarone and desethylamiodarone at 10(-6) M reduced basal LDL receptor promoter activity further then with the TRbeta1 alone (to 30% vs. 50% respectively, p<0.01) but interestingly in combination with T3 these compunds show a synergistic effect on promoter activity (to 225% T3 alone vs. 380% respectively, p<0.01). Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9712728     DOI: 10.1006/bbrc.1998.9174

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

1.  Statin resistant dyslipidemia in a patient treated with amiodarone.

Authors:  Ahmad Al-Sarraf; Min Li; Jiri Frohlich
Journal:  BMJ Case Rep       Date:  2011-10-11

2.  The thyromimetic T-0681 protects from atherosclerosis.

Authors:  Ivan Tancevski; Andreas Wehinger; Egon Demetz; Julia Hoefer; Philipp Eller; Eva Huber; Ursula Stanzl; Kristina Duwensee; Kristina Auer; Wilfried Schgoer; Volker Kuhn; Catherine Fievet; Frans Stellaard; Mats Rudling; Bernhard Foeger; Josef R Patsch; Andreas Ritsch
Journal:  J Lipid Res       Date:  2008-12-22       Impact factor: 5.922

Review 3.  Human low-density lipoprotein receptor gene and its regulation.

Authors:  Wei-Jia Kong; Jingwen Liu; Jian-Dong Jiang
Journal:  J Mol Med (Berl)       Date:  2005-11-16       Impact factor: 4.599

Review 4.  Effects of adiposity on plasma lipid response to reductions in dietary saturated fatty acids and cholesterol.

Authors:  Michael R Flock; Michael H Green; Penny M Kris-Etherton
Journal:  Adv Nutr       Date:  2011-04-30       Impact factor: 8.701

5.  Thyroid and Cardiovascular Disease: Research Agenda for Enhancing Knowledge, Prevention, and Treatment.

Authors:  Anne R Cappola; Akshay S Desai; Marco Medici; Lawton S Cooper; Debra Egan; George Sopko; Glenn I Fishman; Steven Goldman; David S Cooper; Samia Mora; Peter J Kudenchuk; Anthony N Hollenberg; Cheryl L McDonald; Paul W Ladenson
Journal:  Thyroid       Date:  2019-05-13       Impact factor: 6.568

6.  Thyroid and Cardiovascular Disease Research Agenda for Enhancing Knowledge, Prevention, and Treatment.

Authors:  Anne R Cappola; Akshay S Desai; Marco Medici; Lawton S Cooper; Debra Egan; George Sopko; Glenn I Fishman; Steven Goldman; David S Cooper; Samia Mora; Peter J Kudenchuk; Anthony N Hollenberg; Cheryl L McDonald; Paul W Ladenson
Journal:  Circulation       Date:  2019-05-13       Impact factor: 29.690

7.  Thyroid hormone induction of human cholesterol 7 alpha-hydroxylase (Cyp7a1) in vitro.

Authors:  Jan A Lammel Lindemann; Anusha Angajala; David A Engler; Paul Webb; Stephen D Ayers
Journal:  Mol Cell Endocrinol       Date:  2014-02-25       Impact factor: 4.102

8.  Thyroid hormone beta receptor activation has additive cholesterol lowering activity in combination with atorvastatin in rabbits, dogs and monkeys.

Authors:  B R Ito; B-H Zhang; E E Cable; X Song; J M Fujitaki; D A MacKenna; C E Wilker; B Chi; P D van Poelje; D L Linemeyer; M D Erion
Journal:  Br J Pharmacol       Date:  2009-01-22       Impact factor: 8.739

Review 9.  The resurgence of thyromimetics as lipid-modifying agents.

Authors:  Ivan Tancevski; Philipp Eller; Josef R Patsch; Andreas Ritsch
Journal:  Curr Opin Investig Drugs       Date:  2009-09

10.  Adiposity blunts the positive relationship of thyrotropin with proprotein convertase subtilisin-kexin type 9 levels in euthyroid subjects.

Authors:  Arjan J Kwakernaak; Gilles Lambert; Anneke C Muller Kobold; Robin P F Dullaart
Journal:  Thyroid       Date:  2013-02       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.